Prescriber Resources

REVLIMID® (lenalidomide) in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM).

REVLIMID is indicated as maintenance therapy in patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT).

REVLIMID is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1–risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

REVLIMID is indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.

Enrolling in REVLIMID REMS®

In order to prescribe REVLIMID, you must enroll in the REVLIMID REMS® program (formerly known as the RevAssist® program) and agree to follow the requirements of the program. You can enroll by visiting CelgeneRiskManagement.com, a website that allows prescribers to handle the REMS process for all of the Celgene REMS programs. You can also download the Prescriber Enrollment Form below and fax it to Celgene Customer Care at 1-888-432-9325.

Prescribing REVLIMID for your patients

In order to receive REVLIMID, your patients must also be enrolled in the REVLIMID REMS® program. You can enroll your patients, and fill out a prescription form using CelgeneRiskManagement.com. You and your patients can also complete your mandatory confidential surveys there.

Additionally, you can also enroll your patients and write prescriptions by downloading the Desktop Software and installing it on your computer.

Learning more about REVLIMID REMS®

For additional information about the REVLIMID REMS® program, please see the educational materials below.


Please report adverse drug experiences that are suspected to be associated with the use of REVLIMID and any suspected pregnancy occurring during the treatment with REVLIMID to Celgene using any of the following methods:

REPORTING TO CELGENE

Email:

Telephone:

1-908-673-9667

Toll-free:

1-800-640-7854 (Global Drug Safety & Risk Management) or
1-888-423-5436 (Celgene Customer Care Center)

Fax:

1-908-673-9115

Mail to:

Global Drug Safety & Risk Management
Celgene Corporation
556 Morris Avenue
Building S12
Summit, New Jersey 07901

REPORTING TO THE FDA

Adverse drug experiences that are suspected to be associated with the use of REVLIMID and
any suspected pregnancy occurring during the treatment with REVLIMID may also be reported
to the FDA MedWatch Reporting System using any of the following methods:

Online:

Telephone:

1-800-FDA-1088

Fax:

1-800-FDA-0178

Mail to:

MedWatch
5600 Fishers Lane
Rockville, MD 20852-9787

For additional information about the REVLIMID REMS® program, please contact the Celgene Customer Care Center at 1-888-423-5436

Download the
Celgene REMS mobile app
for CelgeneRiskManagement.com
to your iPad here: